Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells

Blood

Volumn 104, Issue 6, 2004, Pages 1816-1824

  Banker, Deborah E ^a   Mayer, Sasha J ^b   Li, Henry Y ^b   Willman, Cheryl L ^b   Appelbaum, Frederick R ^b   Zager, Richard A ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CHOLESTEROL; CYTARABINE; DAUNORUBICIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CHILD; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; SENSITIZATION;

EID: 4444257328     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-01-0395     Document Type: Article

References (28)

1. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425-430.
2. Allayee H, Laffitte BA, Lusis AJ. An absorbing study of cholesterol. Science. 2000;290:1709-1711.
3. Betteridge DJ, Krone W, Ford JM, Gallon DJ. Regulation of sterol synthesis in leukaemia blast cells: a defect resembling familial hypercholesterolaemia. Eur J Clin Invest 1979;9:439-441.
4. Tatidis L, Gruber A, Vitols S. Decreased feedback regulation of low density lipoprotein receptor activity by sterols in leukemic cells from patients with acute myelogenous leukemia. J Lipid Res. 1997;38:2436-2445.
5. Vitols S, Norgren S, Juliusson G, Tatidis L, Luthman H. Multilevel regulation of low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in normal and leukemic cells. Blood. 1994;84:2689-2698.
6. Ho YK, Smith RG, Brown MS, Goldstein JL. Low-density lipoprotein (LDL) receptor activity in human acute myelogenous leukemia cells. Blood. 1978;52:1099-1114.
7. Vitols S, Gahrton G, Ost A, Peterson C. Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood. 1984;63:1186-1193.
8. Rudling M, Gåfvels M, Parini P, Gahrton G, Angelin B. Lipoprotein receptors in acute myelogenous leukemia. Am J Pathol. 1998;153:1923-1935.
9. Vitols S, Angelin B, Ericsson S, et al. Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc Natl Acad Sci USA. 1990;87:2598-602.
10. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses. Blood. 2003;101:3628-3634.
11. Stirewalt DL, Appelbaum FR, Willman CL, Zager RA, Banker DE. Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with Ras hotspot mutations or overexpression. Leuk. Res. 2003;27:133-145.
12. Dimitroukalos J, Nohynek D, Backway KL, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood. 1999;4:1308-1318.
13. Newman A, Clutterbuck RD, Powles RL, Catovsky D, Millar JL. A comparison of the effect of HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma. 1997;24:533-537.
14. Clutterbuck RD, Millar BC, Powles RL, et al. Inhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) mice. Br J Haematol. 1998;102:522-527.
15. Minden MD, Dimitroulakos J, Nohynek D, Penn LZ. Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia. Leuk Lymphoma. 2001;40:659-662.
16. Thibault A, Samid D, Tompkins AC, et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res. 1996;2:483-491.
17. Kim WS, Kim MM, Choi HJ, et al. Phase II study of high-dose lovastatin in patients with advanced gastric adenocarcinoma. Invest. New Drugs. 2001;19:81-83.
18. Lamer J, Jane J, Laws E, Packer R, Myers C, Shaffrey M. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. Am J Clin Oncol. 1998;21:579-583.
19. Kawata S, Yamasaki E, Nagase T, et al. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer. 2001;84:886-891.
20. Wu JC, Merlino G, Cveklova K, Mosinger B Jr, Fausto N. Autonomous growth in serum-free medium and production of hepatocellular carcinomas by differentiated hepatocyte lines that overexpress transforming growth factor alpha 1. Cancer Res. 1994;54:5964-5973.
21. Banker DE, Groudine M, Norwood T, Appelbaum FR. Measurement of spontaneous and therapeutic agent-induced apoptosis with Bcl-2 protein expression in acute myeloid leukemia. Blood. 1997;89:243-255.
22. Stirewalt DL, Willman CL, Radich JP. Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific. Leuk Res. 2002;25:1085-1088.
23. Vitols S, Angelin B, Ericsson S, et al. Uptake of low density lipoproteins by human leukemic cells in vivo: relation to plasma lipoprotein levels and possible relevance for selective chemotherapy. Proc Natl Acad Sci U S A. 1990;87:2598-2602.
24. Maranhao RC, Roland IA, Toffoletto O, et al. Plasma kinetic behavior in hyperlipidemic subjects of a lipidic microemulsion that binds to low density lipoprotein receptors. Lipids. 1997;32:627-633.
25. Versluis AJ, Rump ET, Rensen PC, van Berkel TJ, Bijsterbosch MK. Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo. J Pharmacol Exp Ther. 1999;289:1-7.
26. Agarwal B, Bhendwal S, Halmos B, Moss SF, Ramey WG, Holt PR. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells [comment]. Clin Cancer Res. 1999;5:2223-2229.
27. Dimitroulakos J, Ye LY, Benzaquen M, et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications Clin Cancer Res. 2001;7:158-167.
28. Vitols S, Angelin B, Juliusson G. Simvastatin impairs mitogen-induced proliferation of malignant B-lymphocytes from humans-in vitro and in vivo studies. Lipids. 1997;32:255-262.